See more : Paychex, Inc. (0KGE.L) Income Statement Analysis – Financial Results
Complete financial analysis of Medite Cancer Diagnostics, Inc. (MDIT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medite Cancer Diagnostics, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Gores Holdings VI, Inc. (GHVI) Income Statement Analysis – Financial Results
- Trainline Plc (TNLIY) Income Statement Analysis – Financial Results
- Mulkia Investment Co. (9585.SR) Income Statement Analysis – Financial Results
- Shinpoong Paper Mfg. Co., Ltd (002870.KS) Income Statement Analysis – Financial Results
- PETRONAS Dagangan Berhad (PNADF) Income Statement Analysis – Financial Results
Medite Cancer Diagnostics, Inc. (MDIT)
About Medite Cancer Diagnostics, Inc.
Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.
| Metric | 2017 | 2016 | 2015 |
|---|---|---|---|
| Revenue | 6.81M | 9.24M | 9.89M |
| Cost of Revenue | 6.94M | 5.82M | 6.26M |
| Gross Profit | -131.00K | 3.42M | 3.63M |
| Gross Profit Ratio | -1.92% | 36.98% | 36.67% |
| Research & Development | 1.19M | 1.48M | 1.28M |
| General & Administrative | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 5.16M | 3.60M | 2.95M |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.35M | 5.08M | 4.23M |
| Cost & Expenses | 13.29M | 10.90M | 10.49M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 849.00K | 694.00K | 204.00K |
| Depreciation & Amortization | 293.00K | 214.00K | 177.00K |
| EBITDA | -6.19M | -1.45M | -422.00K |
| EBITDA Ratio | -90.81% | -15.66% | -4.27% |
| Operating Income | -6.48M | -1.66M | -599.00K |
| Operating Income Ratio | -95.11% | -17.98% | -6.06% |
| Total Other Income/Expenses | -818.00K | -634.00K | -182.00K |
| Income Before Tax | -7.30M | -2.30M | -781.00K |
| Income Before Tax Ratio | -107.12% | -24.84% | -7.90% |
| Income Tax Expense | -487.00K | -132.00K | 78.00K |
| Net Income | -6.81M | -2.16M | -859.00K |
| Net Income Ratio | -99.97% | -23.41% | -8.69% |
| EPS | -0.26 | -0.10 | -0.04 |
| EPS Diluted | -0.26 | -0.10 | -0.04 |
| Weighted Avg Shares Out | 26.44M | 21.42M | 20.19M |
| Weighted Avg Shares Out (Dil) | 26.44M | 21.42M | 20.19M |
Source: https://incomestatements.info
Category: Stock Reports